Shares of Devonian Health Group Inc. (CVE:GSD – Get Free Report) traded down 10.3% during trading on Thursday . The stock traded as low as C$10.00 and last traded at C$10.00. 1,800 shares were traded during mid-day trading, an increase of 50% from the average session volume of 1,201 shares. The stock had previously closed at C$11.15.
Devonian Health Group Price Performance
The stock has a market capitalization of C$27.81 million, a price-to-earnings ratio of -2.88 and a beta of 0.46. The company has a debt-to-equity ratio of 16.36, a quick ratio of 7.82 and a current ratio of 1.07. The company has a fifty day simple moving average of C$11.12 and a two-hundred day simple moving average of C$11.78.
Devonian Health Group Company Profile
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products.
See Also
- Five stocks we like better than Devonian Health Group
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
